Antibody-Drug Conjugates With HER2-targeting Antibodies From Synthetic Antibody Libraries Are Highly Potent Against HER2-positive Human Gastric Tumor in Xenograft Models

mAbs - United States
doi 10.1080/19420862.2018.1541370
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

A Novel Asymmetrical Anti-Her2/Cd3 Bispecific Antibody Exhibits Potent Cytotoxicity for HER2-positive Tumor Cells

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2019English

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

Cancer Cell
Cancer ResearchOncologyCell Biology
2016English

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

Cancer Cell
Cancer ResearchOncologyCell Biology
2019English

APOMAB® Antibody Drug Conjugates Targeting Dead Tumor Cells Are Effective in Vivo

Molecular Cancer Therapeutics
Cancer ResearchOncology
2018English

Affinity Maturation of Monoclonal Antibody 1E11 by Targeted Randomization in CDR3 Regions Optimizes Therapeutic Antibody Targeting of HER2-Positive Gastric Cancer

PLoS ONE
Multidisciplinary
2015English

Antibody–Drug Conjugate Hits Elusive HER2 + Breast Tumors

Cancer Discovery
Oncology
2013English

T-Dm1, a Novel Antibody-Drug Conjugate, Is Highly Effective Against Uterine and Ovarian Carcinosarcomas Overexpressing HER2

Clinical and Experimental Metastasis
MedicineCancer ResearchOncology
2014English

Monodisperse Polysarcosine-Based Highly-Loaded Antibody-Drug Conjugates

Chemical Science
Chemistry
2019English

Bispecifics and Antibody–drug Conjugates: A Positive Synergy

Drug Discovery Today: Technologies
BiotechnologyDrug DiscoveryMolecular Medicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy